|Bid||361.50 x 0|
|Ask||361.70 x 0|
|Day's Range||361.50 - 373.90|
|52 Week Range||212.70 - 413.20|
|PE Ratio (TTM)||35.90|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
This highly levered, acquisition-focused growth story has come crashing down recently. It is eerily similar to when the highly-levered, acquisition-focused growth story of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) fell apart not too long ago. As we all know, VRX stock went bust and hasn’t recovered.
The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.